Researchers at St. Jude Children’s Research Hospital have discovered analogs of two bacterial natural products, FR901464 and pladienolide, known for their selective and potent in vivo anti-cancer activity. The analogs, designated sudemycins, are made synthetically and have similar anti-cancer activity but improved solubility and stability. They also have the potential to be developed into targeted anticancer drugs useful in treating cancer and disorders associated with pre-mRNA splicing dysregulation. Multiple lead compounds show real potential for the treatment of multiple cancers including certain subtypes of melanoma, leukemia, glioblastoma, and many others.
sudemycin, pladienolide, cancer, natural product analogs
Granted Patents or Published Applications
US Patent Application Pending, published July 21, 2011 as U.S. 2011-0178098
Related Scientific References
Convertini P. et al., “Sudemycin E influences alternative splicing and changes chromatin modifications,” Nucleic Acids Res. (2014, Mar 11);
Lagisetti, C. et al., “Optimization of antitumor modulators of pre-mRNA splicing,” J Med Chem. (2013);
Lagisetti, C. et al., “Antitumor Compounds Based on a Natural Product Consensus Pharmacophore”, J. Med. Chem. (2008).
This technology is subject to an exclusive license option until March 1, 2020.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.